SharesGrow.com Intrinsic Value of S&P & Nasdaq Contact Us

हिन्दी

← Back to all stocks

Procyon Corporation PCYN OTC

Other OTC • Healthcare • Drug Manufacturers - Specialty & Generic • US • USD

SharesGrow Score

SharesGrow Intrinsic Value

Negative cash flow

Procyon Corporation (PCYN) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $0.28. It has a SharesGrow Score of 33/100, indicating a weak investment profile with 0 out of 7 criteria passed.

Financials: revenue is $7M, +12.3%/yr average growth. Net income is $33,890, growing at -131%/yr. Net profit margin is 0.5% (thin). Gross margin is 31.9% (-40.1 pp trend).

Balance sheet: total debt is $139,206 against $2M equity (Debt-to-Equity (D/E) ratio 0.06, conservative). Current ratio is 2.55 (strong liquidity). Debt-to-assets is 4%. Total assets: $3M.

SharesGrow 7-Criteria breakdown: Value 15/100 (Fail), Growth 48/100 (Partial), Past 25/100 (Fail), Health 67/100 (Partial), Moat 21/100 (Fail), Future ?/100 (Fail), Income 30/100 (Fail).

PCYN SharesGrow Score Overview

34/100

SharesGrow Score

Below average — proceed with caution

View full scorecard →

VALUE 15/100

Valuation — P/E, PEG, Forward PEG

GROWTH 48/100

Financials — average growth

PAST 25/100

strong — trend

HEALTH 67/100

Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is

MOAT 21/100

Gross margin is + market cap

FUTURE 0/100

Analyst outlook — as buy

INCOME 30/100

Net profit margin is

Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — PCYN

PCYN trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.

View details →

PCYN: +12.3%/yr revenue is, -131%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.

View details →

PCYN: 1 / 4 years profitable. weak. Score = 1 / 4 × 100. ≥ 80 = Pass.

View details →

Balance sheet PCYN: Debt-to-Equity (D/E) ratio 0.06 (conservative), Current ratio is 2.55 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.

View details →

PCYN: Gross margin is 31.9% (-40.1 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 21/100. ≥ 70 = Pass.

View details →

No analyst coverage available for this stock.

PCYN: Net profit margin is 0.5%. thin (0-5%). Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.

View details →

Stock Chart & Stats

Market Data

52-Week Range0.0013-0.28

Volume2.5K

Avg Volume (30D)567

Market Cap$2.27M

Beta (1Y)-1.03

Share Statistics

EPS (TTM)0.00

Shares Outstanding$8.14M

IPO Date1996-12-11

Employees19

CEOJustice W. Anderson

Financial Highlights & Ratios

Revenue (TTM)$6.67M

Gross Profit$2.13M

EBITDA$277.84K

Net Income$33.89K

Operating Income$-446.53K

Total Cash$413.47K

Total Debt$139.21K

Net Debt$58.5K

Total Assets$3.45M

Price / Earnings (P/E)121.7

Price / Sales (P/S)0.34

Analyst Forecast

Company Info

CountryUS

ExchangeOther OTC

CurrencyUSD

ISINUS7428063009

Price Chart

PCYN

Procyon Corporation ↗ · Other OTC

Healthcare • Drug Manufacturers - Specialty & Generic

0.00 52WK RANGE 0.28

People Also View

Sumitomo Pharma Co., Ltd.

Nippon Shinyaku Co., Ltd.

Genomma Lab Internacional, S.A.B. de C.V.

Cumberland Pharmaceuticals Inc.

RAMM Pharma Corp.

The BC Bud Corporation

Contact Us

🎓

SharesGrow Academy

Learn how to calculate Intrinsic Value and find undervalued stocks.

Weekly live sessions

📧 [email protected]

📞 +65 8912 8000

Send us a message